Dr. Eskelund on Outcomes of TP53-Mutated MCL

Christian Winther Eskelund, MD
Published: Wednesday, Oct 11, 2017



Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

The significant findings of a study investigating TP53 mutations were that patients who had TP53 mutations did far worse than patients who had no mutations, states Eskelund. The median overall survival was 1.8 years versus 12 years for non-mutated patients.

TP53 is normally associated with poor outcomes in hematologic malignancies, making this an expected outcome, according to Eskelund.
 


Christian Winther Eskelund, MD, Copenhagen University Hospital, Rigshospitalet, discusses outcomes for patients with TP53-mutated mantle cell lymphoma (MCL).

The significant findings of a study investigating TP53 mutations were that patients who had TP53 mutations did far worse than patients who had no mutations, states Eskelund. The median overall survival was 1.8 years versus 12 years for non-mutated patients.

TP53 is normally associated with poor outcomes in hematologic malignancies, making this an expected outcome, according to Eskelund.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x